Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 4/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347808 | 0.89 | PDK1 (0.41) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL347482 | 0.87 | PDK1 (0.43) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL348230 | 0.87 | PDK1 (0.39) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL348063 | 0.86 | PDK1 (0.44) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL346166 | 0.86 | PDK1 (0.42) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL347807 | 0.86 | HTT (0.46) | KCNH2PDK1PDK2PDK3PDK4 | |
| SCHEMBL346167 | 0.85 | PDK1 (0.41) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL346243 | 0.84 | PDK1 (0.41) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL348091 | 0.82 | PDK1 (0.42) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL347576 | 0.78 | EPHX2 (0.40) | ALDH1A1NPSR1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | KCNH2 2332/4885PDK1 3480/4885PDK2 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.